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Conclusion: Using pangenomic microarrays, we identified and compared
the gene profiles of preconditioning and postconditioning versus IR in the
mouse left ventricle in vivo. Among the genes jointly downregulated by pre-
conditioning and postconditioning, Zac1 was identified as a putative cardio-
protective key regulator. Indeed downregulation at the transcriptional and
protein levels of Zac1 leads to cardioprotection against IR.
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Background: We have shown that the Sonic Hedgehog (Shh) embryonic
signalling pathway can be reactivated in myocardial infarction (MI) in adults
inducing expression of pro-angiogenic factors. We hypothesized that com-
bining Shh gene therapy and endothelial BM-derived pro-angiogenic cell
mobilization by a CXCR4 antagonist, AMD3100 (AMD), could exert syner-
gistic effects and would be superior to either single strategy for the treatment
of MI.
Methods/results: In vivo, MI was induced in WT and GFP-bone marrow
(BM) transplanted mice randomly assigned in 4 treatment groups: control;
AMD (single dose, 5mg/kg s.c.); Shh (intramyocardial; 100μg Shh plasmid
DNA at time of MI surgery); AMD+Shh group. Left ventricular ejection frac-
tion (LVEF) was evaluated by echo up to 4 weeks post MI. AMD+Shh group
exhibited the best LV function . Furthermore, combination of AMD with sub-
therapeutic dose of Shh resulted in a significant improvement of cardiac func-
tion recovery compared to monotherapy, highlighting its synergistic effect
(P<0.05). Elastic staining and immunohistological analyses demonstrated
reduced infarct size and increased capillary density in the AMD+Shh group
(both P < 0.05). Combination therapy was also associated with significant
increase in number of GFP-BS lectin BM-derived cells incorporated into the
ischemic area (P<0.05). We then explored the certain potential mechanisms of
the favourable effects of combination therapy. MMP-9 mRNA expression was
increased in ischemic myocardium in the AMD+Shh (10-fold versus control).
The positive effect on EF of combined treatment was attenuated in MMP-9
KO mice, suggesting that MMP-9 might be a key modulator of the combina-
tion therapy.
Conclusion: Pharmacological enhancement of Shh gene therapy via BM-
cell mobilization by a CXCR4 antagonist is mediated via an MMP-9-depen-
dent pathway. The combination may offer advantages in safety and feasibility
by allowing lower dose gene transfer while improving outcome post-MI
257
A novel polysaccharide-based porous scaffold for cell delivery into the
infarcted heart
Catherine Le Visage (1), Olivier Gournay [Orateur] (2), Najah Ben Guirat
(3), Sofiane Hamidi (1), Laetitia Chaussumier (4), Richard Isnard (3), Sté-
phane Hatem (3), Didier Letourneur (1), Françoise Norol (5)
(1) Inserm U698, Bio-ingénierie Cardiovasculaire, CHU X. Bichat, Paris,
France – (2) groupe hospitalier Pitié Salpêtrière, Cardiologie, Paris,
France – (3) Inserm UMRS 956, Faculté de médecine Pierre et Marie
Curie, 75013, France – (4) Inserm U790, Institut Gustave Roussy, Ville-
juif, France – (5) Department of Biotherapy, AP-HP, Groupe Hospitalier
Pitié Salpêtrière, Paris, France
Background: Cellular cardiomyoplasty has been proposed as an attrac-
tive strategy to repair myocardial damage. One of the crucial point is the
optimal delivery strategy. In the present study, we examined the use of an
implantable porous scaffold for promoting bone marrow-derived mesen-
chymal stem cells (MSCs) survival and functions in a rat model of acute
myocardial infarction.
Methods and Results: Cardiac patch was based on biodegradable polysaccha-
rides porous scaffold. After ligation of the left anterior coronary artery, the fate of
1x106 GFP+ MSC administered either using cellularized scaffold implantation or
direct injection was examined at 1 and 2 months. The number of residual GFP+
cells in the sample studied was estimated on the basis of the fluorescence emitted
by a defined number of GFP+ cells used for calibration. Cellularized scaffold
allowed a more efficient delivery and the difference with direct injection was sig-
nificant at 2 months, with respectively 2100±1300×103 and 215±85x103 residual
GFP+ cells (p<0.03). Cardiac tissue levels of matrix metalloproteinase-2 and -9
mRNA were similar whatever the administration conditions but a slight increase
in the local production of vascular endothelial growth factor was observed at 2
months after patch implantation in comparison to direct injection (p<0.05). In ani-
mals having received MSC implemented on scaffold, clusters of GFP+ cells,
mainly phenotypically consistent with immature MSC cells, were detected in the
peri-infarct area. The increased survival using scaffold was not translated in an
improved myocardial remodelling and functions with no significant difference in
the LVEDD, LVESD, and FS between the 2 groups as in comparison with animals
implanted with non cellularized scaffold.
Conclusions: These findings demonstrate that the implantation of cellular-
ized grafts is safe and effective for delivering mesenchymal stem cells into
damaged myocardium, and results in a better cellular engraftment compared to
direct injection.
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We investigated whether postischemic cardiac remodeling (REM) is accel-
erated in diabetic rats with possible involvement of thyroid hormone (TH) sig-
naling in this response. Changes in TH signaling occur during REM after acute
myocardial infarction (MI) and contribute to cardiac dysfunction.
Diabetes was induced in Wistar rats by streptozotocin injection (35mg/Kg
i.p.). After 30 days diabetic rats (DM-AMI, n=9) were subjected to MI, while
control rats were either sham-operated (SHAM, n=10) or subjected to MI
(AMI(1), n=10). After 2 weeks, TRα1 and TRα1 expression and TH levels
were measured. Hypothyroid rats by propyl-thiouracil administration (0.05%)
in water for 3 weeks were subjected to MI (HYPO-AMI, n=6) while untreated
MI rats served as controls (AMI(2), n=6). LV dimensions (LVEDD and
LVEDS) and ejection fraction (EF%) were used to assess contractility and
REM 2 weeks after MI using echocardiography. Cardiac function was mark-
edly decreased in DM –AMI.
In AMI(1), TRα1 and TRβ1 protein expression were not changed signifi-
cantly as compared to SHAM while in DM-AMI, both TRα1 and TRβ1 were
decreased 1.7 and 1.9 fold respectively as compared to SHAM, p<0.05. T3 and
T4 levels were not different between groups. HYPO-AMI hearts, with scar areas
comparable to AMI(2) hearts [97(4.7) vs 105 (10.3), p>0.05], showed a similar
unfavorable functional response : EF% was found to be markedly reduced [24
(0.9) in HYPO-AMI vs 36.2 (1.0) in AMI(2), p<0.05], while LVEDS was 8.3
(0.2) for HYPO-AMI and 7.5(0.1) for AMI(2), p<0.05. LVEDD equally
increased in the 2 groups. Postischemic cardiac remodeling is accelerated both
in hypothyroid and diabetic hearts. Tissue hypothyroidism which occurs in DM
after myocardial infarction,may at least in part, account for this response.
 Scar (mm2) LVEDD (mm) LVEDS (mm) EF%
SHAM ----- 6.5 (0.1) 3.8 (0.2) 76 (2.6)
AMI(1) 79 (4.0) 7.7 (0.2)* 5.7 (0.2)* 52 (1.5)*
DM-AMI 83 (4.9) 8.5 (0.2)** 7.0 (0.3)** 39 (2.1)**
*p<0.05 vs SHAM, **p<0.05 vs SHAM and AMI(1)
